Tradestie Institutional Equity Comparison Engine · Market Close Nov 17, 2026

MLAB vs TCX: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

MLAB Wins Head-to-Head Institutional Verdict (4–2 across 6 Pillars · 8–2 Matrix Metrics)

MLAB Overall Winner 6-Pillar Tally: MLAB 4 – 2 TCX Matrix Metrics: MLAB 8 – 2 TCX

As of Nov 17, 2026, Mesa Laboratories Inc (MLAB) is the stronger overall head-to-head candidate over Tucows, Inc (TCX) in the Tradestie Institutional Equity Comparison Engine, winning 8–2 core matrix metrics and 4–2 across our 6-pillar institutional scorecard (led by Growth & Scale, Profitability & Quality, Balance Sheet & Cash Flow). MLAB carries a Unified Composite Score of 41.8/100 (SELL) at $134.19 (24.9x Forward P/E, 10.4% operating margin), whereas TCX carries 44.1/100 (HOLD) at $14.55 (30.5x Forward P/E, -4.3% operating margin).

  • Composite vs. Pillar Nuance: While TCX currently prints a higher short-term Unified Composite Score (44.1/100 HOLD vs. MLAB 41.8/100 SELL), MLAB captures the overall institutional head-to-head verdict (8–2 matrix metrics and 4–2 across the 6 pillars) due to superior fundamental profitability (10.4% vs. -4.3% operating margin) and revenue trajectory (+2.6% vs. +1.4% YoY).

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About MLAB vs TCX
MLAB NASDAQ Head-to-Head Winner
Mesa Laboratories Inc
Industrial Instruments For Measurement, Display, And Control
$134.19
+0.07% 1D
Market Cap $781.3M
TTM Revenue $251M
Forward P/E 24.9x
Beta / 30D Vol 1.13β · 52% Vol
Unified Composite Score
41.8 / 100 SELL
Tech 20.0 Fund 36.0 Flow 50.0 Mom 40.0
Weinstein Technical Phase Markup · Hold / add on dips
Price above SMA50, rising 50-day trend (2.9% over 20 days), RSI 55
RSI-14: 54.7 · SMA20: $130.31 · SMA50: $129.37
TCX NASDAQ
Tucows, Inc
Services-Computer Processing & Data Preparation
$14.55
+27.12% 1D
Market Cap $131.2M
TTM Revenue $396M
Forward P/E 30.5x
Beta / 30D Vol 0.45β · 154% Vol
Unified Composite Score
44.1 / 100 HOLD
Tech 5.0 Fund 36.0 Flow 58.0 Mom 50.0
Weinstein Technical Phase Markup · Hold / add on dips
Price above SMA50, rising 50-day trend (5.4% over 20 days), RSI 68
RSI-14: 67.9 · SMA20: $11.90 · SMA50: $10.69

6-Pillar Scorecard Institutional Category Breakdown (MLAB 4 – 2 TCX)

Columns: Metric · MLAB · TCX
1. Valuation Multiples TCX
Forward P/E 24.9x 30.5x
Trailing P/E 119.8x 30.5x
PEG Ratio N/M 1.89x
EV / Revenue 3.1x 1.7x
2. Growth & Scale MLAB
Revenue Growth (YoY) +2.6% +1.4%
Earnings Growth (YoY) +67.0% +90.2%
TTM Revenue (USD) $251M $396M
Market Cap $781.3M $131.2M
3. Profitability & Quality MLAB
Gross Margin 64.8% 36.5%
Operating Margin 10.4% -4.3%
Net Profit Margin 2.6% -17.9%
Return on Equity (ROE) 3.6% -1011.6%
4. Balance Sheet & Cash Flow MLAB
Cash Generation (TTM) $49M EBITDA -$23M
Cash Flow Margin 19.4% EBITDA Mgn -5.7%
Net Cash / Leverage $34.66 Book/Sh · 3.6% ROE $531M Net Debt
Dividend Yield 0.47% None (0.00%)
5. Options & Positioning TCX
Options Structure Phase UNCLASSIFIED CONSOLIDATION
Current IV / %ile N/A (N/A) 67.3% (7th %ile)
Put/Call OI Skew N/A 0.23x (Call-Skewed)
OBV Trend / Tech Phase NEUTRAL · Markup DISTRIBUTION · Markup
6. R&D & Supply-Chain Moat MLAB
OpEx & R&D Intensity 54.4% of Rev ($137M) 40.8% of Rev ($162M)
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Scientific & Technical Instruments Operator Software - Infrastructure Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: MLAB (8) vs TCX (2)
Institutional Metric MLAB TCX Criterion Row Edge
Market Capitalization
Scale
$781.3M $131.2M Larger Scale MLAB
Trailing P/E Ratio
Valuation
119.8x 30.5x Lower Multiple TCX
Forward P/E Ratio
Valuation
24.9x 30.5x Lower Multiple MLAB
Revenue Growth (YoY)
Growth
+2.6% +1.4% Higher Growth MLAB
Operating Margin (TTM)
Profitability
10.4% -4.3% Higher Margin MLAB
Net Profit Margin
Profitability
2.6% -17.9% Higher Margin MLAB
Return on Equity (ROE)
Capital Efficiency
3.6% -1011.6% Higher ROE MLAB
52-Week Range Position
Momentum
86% ($70–$144) 36% ($8–$25) Stronger Trend MLAB
Beta / 30D Volatility
Risk Regime
1.13β · 52% Vol 0.45β · 154% Vol Lower Realized Risk MLAB
Unified Institutional Score
Composite Signal
41.8 / 100 (SELL) 44.1 / 100 (HOLD) Higher Composite TCX
Trailing 12M Revenue (USD)
Operating Scale
$251M $396M FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
64.8% 36.5% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · 3.1x EV/Rev 1.89x PEG · 1.7x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
$49M EBITDA ($34.66 Book/Sh · 3.6% ROE) -$23M ($531M Net Debt) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon TCX +46.67 pp
MLAB: +8.83% · TCX: +55.5%
3M Horizon TCX +30.19 pp
MLAB: +12.09% · TCX: +42.28%
6M Horizon MLAB +36.27 pp
MLAB: +34.42% · TCX: -1.85%
1Y Horizon MLAB +111.13 pp
MLAB: +81.48% · TCX: -29.65%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on MLAB vs TCX. Trailing 12-month operating profitability (MLAB 10.4% vs TCX -4.3%) and valuation multiples (MLAB 24.9x vs TCX 30.5x Forward P/E) are benchmarked directly in Pillar 4 below.

MLAB ADR TTM Benchmark FX-Normalized USD
TTM Revenue$251M
Gross Margin64.8%
Op. Margin10.4%
ROE / Fwd P/E3.6% · 24.9x
TCX ADR TTM Benchmark FX-Normalized USD
TTM Revenue$396M
Gross Margin36.5%
Op. Margin-4.3%
ROE / Fwd P/E-1011.6% · 30.5x

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
MLAB UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew N/A
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact MLAB Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
TCX CONSOLIDATION
71d in phase · OBV DISTRIBUTION
Current IV 67.3%
IV Percentile 7th %ile
Put/Call OI Skew 0.23x (Call-Skewed)
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow DISTRIBUTION
Exact TCX Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
MLAB Moat Profile Cyclical / Execution-Driven Positioning
Scientific & Technical Instruments Operator
Competes within the Scientific & Technical Instruments value chain with $781.3M market capitalization and 10.4% operating margin.
OpEx & R&D Reinvestment 54.4% of Rev ($137M)
90D Engineering Disclosures 0 Published
TCX Moat Profile Cyclical / Execution-Driven Positioning
Software - Infrastructure Operator
Competes within the Software - Infrastructure value chain with $131.2M market capitalization and -4.3% operating margin.
OpEx & R&D Reinvestment 40.8% of Rev ($162M)
90D Engineering Disclosures 0 Published

Investor FAQ MLAB vs TCX Key Questions & Quantitative Answers

As of Nov 17, 2026, Mesa Laboratories Inc (MLAB) is the stronger overall head-to-head candidate over Tucows, Inc (TCX) in the Tradestie Institutional Equity Comparison Engine, winning 8–2 core matrix metrics and 4–2 across our 6-pillar institutional scorecard (led by Growth & Scale, Profitability & Quality, Balance Sheet & Cash Flow). MLAB carries a Unified Composite Score of 41.8/100 (SELL) at $134.19 (24.9x Forward P/E, 10.4% operating margin), whereas TCX carries 44.1/100 (HOLD) at $14.55 (30.5x Forward P/E, -4.3% operating margin). Composite vs. Pillar Nuance: While TCX currently prints a higher short-term Unified Composite Score (44.1/100 HOLD vs. MLAB 41.8/100 SELL), MLAB captures the overall institutional head-to-head verdict (8–2 matrix metrics and 4–2 across the 6 pillars) due to superior fundamental profitability (10.4% vs. -4.3% operating margin) and revenue trajectory (+2.6% vs. +1.4% YoY).

MLAB leads the Growth & Scale pillar: MLAB posts +2.6% YoY revenue growth and +67.0% YoY earnings growth on $251M TTM revenue (64.8% gross margin, 10.4% operating margin), compared with TCX at +1.4% YoY revenue growth and +90.2% YoY earnings growth on $396M TTM revenue (36.5% gross margin, -4.3% operating margin). On trailing 12-month operating scale, MLAB generates $251M in USD-normalized revenue versus $396M for TCX. In operating R&D and SG&A reinvestment, MLAB deploys 54.4% of Rev ($137M) (0 90-day corporate R&D disclosures) versus 40.8% of Rev ($162M) (0 disclosures) for TCX.

TCX screens cheaper on headline valuation multiples. MLAB trades at 24.9x Forward P/E, 119.8x Trailing P/E, N/M PEG, and 3.1x EV/Revenue (19.4% EBITDA margin), whereas TCX trades at 30.5x Forward P/E, 30.5x Trailing P/E, 1.89x PEG, and 1.7x EV/Revenue (-5.7% FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against MLAB (3.6% ROE) versus TCX (-1011.6% ROE) capital efficiency.

In options market volatility and institutional positioning, MLAB carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (1.13β · 52% Vol realized risk). By comparison, TCX carries 67.3% implied volatility (7th %ile, Compressed (<25th %ile)), a 0.23x (Call-Skewed) Put/Call open-interest ratio, DISTRIBUTION on-balance volume, and sits in a CONSOLIDATION options structure phase (0.45β · 154% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 17, 2026. For educational research only; not investment advice.